BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 23822114)

  • 21. Sorafenib enhances proteasome inhibitor-mediated cytotoxicity via inhibition of unfolded protein response and keratin phosphorylation.
    Honma Y; Harada M
    Exp Cell Res; 2013 Aug; 319(14):2166-78. PubMed ID: 23727131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.
    Weintraub JL; Salem R
    J Vasc Interv Radiol; 2013 Aug; 24(8):1123-34. PubMed ID: 23562168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma.
    Arao T; Ueshima K; Matsumoto K; Nagai T; Kimura H; Hagiwara S; Sakurai T; Haji S; Kanazawa A; Hidaka H; Iso Y; Kubota K; Shimada M; Utsunomiya T; Hirooka M; Hiasa Y; Toyoki Y; Hakamada K; Yasui K; Kumada T; Toyoda H; Sato S; Hisai H; Kuzuya T; Tsuchiya K; Izumi N; Arii S; Nishio K; Kudo M
    Hepatology; 2013 Apr; 57(4):1407-15. PubMed ID: 22890726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
    Dai XF; Ding J; Zhang RG; Ren JH; Ma CM; Wu G
    Int J Radiat Biol; 2013 Sep; 89(9):724-31. PubMed ID: 23682582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells.
    Louandre C; Marcq I; Bouhlal H; Lachaier E; Godin C; Saidak Z; François C; Chatelain D; Debuysscher V; Barbare JC; Chauffert B; Galmiche A
    Cancer Lett; 2015 Jan; 356(2 Pt B):971-7. PubMed ID: 25444922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion.
    Sprinzl MF; Puschnik A; Schlitter AM; Schad A; Ackermann K; Esposito I; Lang H; Galle PR; Weinmann A; Heikenwälder M; Protzer U
    J Hepatol; 2015 Apr; 62(4):863-70. PubMed ID: 25463538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathways and targets in hepatocellular carcinoma.
    Psyrri A; Arkadopoulos N; Vassilakopoulou M; Smyrniotis V; Dimitriadis G
    Expert Rev Anticancer Ther; 2012 Oct; 12(10):1347-57. PubMed ID: 23176622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.
    Tovar V; Cornella H; Moeini A; Vidal S; Hoshida Y; Sia D; Peix J; Cabellos L; Alsinet C; Torrecilla S; Martinez-Quetglas I; Lozano JJ; Desbois-Mouthon C; Solé M; Domingo-Domenech J; Villanueva A; Llovet JM
    Gut; 2017 Mar; 66(3):530-540. PubMed ID: 26658144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Additive antitumour response to the rabbit VX2 hepatoma by combined radio frequency ablation and toll like receptor 9 stimulation.
    Behm B; Di Fazio P; Michl P; Neureiter D; Kemmerling R; Hahn EG; Strobel D; Gress T; Schuppan D; Wissniowski TT
    Gut; 2016 Jan; 65(1):134-43. PubMed ID: 25524262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.
    Liu LP; Ho RL; Chen GG; Lai PB
    Clin Cancer Res; 2012 Oct; 18(20):5662-71. PubMed ID: 22929805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early prediction of response of sorafenib on hepatocellular carcinoma by CT perfusion imaging: an animal study.
    Wang Q; Shi G; Wang L; Liu X; Wu R
    Br J Radiol; 2014 Mar; 87(1035):20130695. PubMed ID: 24452058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
    Smolle E; Taucher V; Petru E; Haybaeck J
    Anticancer Res; 2014 Apr; 34(4):1519-30. PubMed ID: 24692678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advantage of sorafenib combined with radiofrequency ablation for treatment of hepatocellular carcinoma.
    Tang Z; Kang M; Zhang B; Chen J; Fang H; Ye Q; Jiang B; Wu Y
    Tumori; 2017 May; 103(3):286-291. PubMed ID: 28058713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-invasive monitoring of the therapeutic response in sorafenib-treated hepatocellular carcinoma based on photoacoustic imaging.
    Lee S; Kim JH; Lee JH; Lee JH; Han JK
    Eur Radiol; 2018 Jan; 28(1):372-381. PubMed ID: 28752217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells.
    Fernando J; Malfettone A; Cepeda EB; Vilarrasa-Blasi R; Bertran E; Raimondi G; Fabra À; Alvarez-Barrientos A; Fernández-Salguero P; Fernández-Rodríguez CM; Giannelli G; Sancho P; Fabregat I
    Int J Cancer; 2015 Feb; 136(4):E161-72. PubMed ID: 25053293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
    Gao DY; Lin TsT; Sung YC; Liu YC; Chiang WH; Chang CC; Liu JY; Chen Y
    Biomaterials; 2015 Oct; 67():194-203. PubMed ID: 26218745
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sorafenib after RFA in HCC patients: a pilot study.
    de Stefano G; Farella N; Scognamiglio U; Liorre G; Calabria G; Ascione T; Giorgio A; Iodice V
    Hepatogastroenterology; 2015; 62(138):261-3. PubMed ID: 25916044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β-catenin pathway and receptor tyrosine kinases.
    Lu YY; Wang JJ; Zhang XK; Li WB; Guo XL
    J Pharm Pharmacol; 2015 Oct; 67(10):1393-405. PubMed ID: 26076716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy.
    Park JG; Park SY; Lee HW
    World J Gastroenterol; 2015 Feb; 21(8):2568-72. PubMed ID: 25741170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects.
    Zhang W; Zhu XD; Sun HC; Xiong YQ; Zhuang PY; Xu HX; Kong LQ; Wang L; Wu WZ; Tang ZY
    Clin Cancer Res; 2010 Jul; 16(13):3420-30. PubMed ID: 20570927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.